CCS
AGIO icon

Crosspoint Capital Strategies’s Agios Pharmaceuticals AGIO Stock Holding History

Crosspoint Capital Strategies’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-94
Closed -$10K – 751
2015
Q2 		$10K Buy
+94
New +$10.1K ﹤0.01% 517
2015
Q1 		– Sell
-39,770
Closed -$4.46M – 508
2014
Q4 		$4.46M Buy
+39,770
New +$3.55M 1.55% 5

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Crosspoint Capital Strategies's AGIO Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Agios Pharmaceuticals (AGIO) in Q3 2015, closing a stake of 94 shares — an estimated $10K sold.

Crosspoint Capital Strategies first reported a position in AGIO in Q4 2014 and held it in 2 quarters. The position peaked at $4.46M in Q4 2014. 151 funds tracked by Wall St. Rank hold AGIO as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Agios Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 94 Agios Pharmaceuticals shares in Q3 2015, an estimated $10K.
  • Crosspoint Capital Strategies first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Agios Pharmaceuticals position peaked at $4.46M in Q4 2014.
  • 151 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.